Literature DB >> 6292610

Unexpected opioid activity in a known class of drug.

D Römer, H H Büscher, R C Hill, R Maurer, T J Petcher, H Zeugner, W Benson, E Finner, W Milkowski, P W Thies.   

Abstract

Tifluadom, although structurally a 1,4 benzodiazepine, has no affinity for the 3H-flunitrazepam binding site, but is a potent displacer of 3H-bremazocine from its opioid binding site. Tifluadom is characterised as an opiate kappa-receptor agonist in vitro and in vivo with potent analgesic activity in animals and no dependence potential.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6292610     DOI： 10.1016/0024-3205(82)90346-0

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  5 in total

1.  Behavioural effects of selective mu-, kappa-, and delta-opioid agonists in neonatal rats.

Authors:  H C Jackson; I Kitchen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

3.  On the mechanisms of kappa-opioid-induced diuresis.

Authors:  T P Blackburn; K R Borkowski; J Friend; M J Rance
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

4.  Effects of diazepam on nociception in rats.

Authors:  F Zambotti; N Zonta; R Tammiso; F Conci; B Hafner; L Zecca; P Ferrario; P Mantegazza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

5.  Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment.

Authors:  Amanda N Nieman; Guanguan Li; Nicolas M Zahn; Md Yeunus Mian; Brandon N Mikulsky; Dylan A Hoffman; Taylor M Wilcox; Alexander S Kehoe; Ian W Luecke; Michael M Poe; David Alvarez-Carbonell; James M Cook; Douglas C Stafford; Leggy A Arnold
Journal:  ACS Chem Neurosci       Date:  2020-06-18       Impact factor: 5.780
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.